Drug intelligence / Profile preview

[18F]DPA-714

Development stage: Unknown
Lead developer: Bayer
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[18F]DPA-714 is a radioactive tracer used in Positron Emission Tomography (PET) imaging that specifically binds to the 18-kDa translocator protein (TSPO), formerly known as the peripheral benzodiazepine receptor. This radiotracer is designed to visualize neuroinflammation in the brain by targeting TSPO, which is expressed at higher levels in activated microglia during inflammatory processes. It has shown promise in clinical trials for imaging neuroinflammation in various neurological conditions including Alzheimer's disease, epilepsy, and autoimmune encephalitis.

Other names: N,N-diethyl-2-(2-(4-(2-[18F]-fluoroethoxy)phenyl)5,7-dimethylpyrazolo[1,5a]pyrimidin-3-yl)acetamide

Targets

TSPO (Translocator Protein (18 kDa))

Beyond the preview

Go deeper on [18F]DPA-714.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]DPA-714.

Explore the full profile